Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
P/S ratio for Medios AG (ILM1.DE)
P/S ratio as of 2023: 0.21
According to Medios AG's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.21. At the end of 2022 the company had a P/S ratio of 0.26.
P/S ratio history for Medios AG from 2009 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.21 |
| 2022 | 0.26 |
| 2021 | 0.57 |
| 2020 | 0.92 |
| 2019 | 0.74 |
| 2018 | 0.58 |
| 2017 | 1.00 |
| 2016 | 0.25 |
| 2015 | 1699.57 |
| 2014 | 50.80 |
| 2013 | 651.62 |
| 2012 | 6.03 |
| 2011 | 0.17 |
| 2010 | 7.02 |
| 2009 | 0.00 |